iPremom Secures Significant Seed Funding
iPremom, a Valencia-based molecular diagnostics company, has successfully secured €15 million in seed funding. The investment round, which took place on September 2, 2026, was led by Amadeus Capital Partners, with additional participation from Asabys Partners and APEX Ventures. iPremom focuses on early-stage detection of pregnancy complications through innovative diagnostics technology.
Funding Details
The funding will be directed toward the clinical validation and commercial launch of iPremom's MaiRa platform. This technology utilizes blood tests to identify early signs of pregnancy complications during the first trimester, aiming to provide a comprehensive molecular picture of pregnancy.
Leadership Insights
Guillermo Ferrando Huertas, CEO of iPremom, is at the helm of the company as it advances its mission to revolutionize pregnancy diagnostics. Professor Carlos Simón, co-founder and Chairman of iPremom, stated: "Pregnancy complications have been under-diagnosed and under-treated for generations, because the field was looking in the wrong place at the wrong time. Our ambition is not just to build a better preeclampsia test, it is to give every pregnant woman a comprehensive, early molecular picture of her pregnancy."
Investors
The investment round was spearheaded by Amadeus Capital Partners, a venture capital firm known for supporting transformative technology ventures. Asabys Partners and APEX Ventures also contributed to the funding, indicating strong investor confidence in iPremom's potential.
Strategic Use of Funds
The newly acquired funds are earmarked for further development of the MaiRa platform, focusing on clinical testing and preparation for commercial rollout. This strategic investment will enable iPremom to advance its diagnostic capabilities and expand its market presence.
The successful funding round marks a significant milestone for iPremom as it continues to develop solutions aimed at improving prenatal care and outcomes.